- Home
- BTSG vs AKRO Comparison
BTSG vs AKRO Comparison
Compare BTSG & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTSG
- AKRO
- Stock Information
- Founded
- BTSG 1974
- AKRO 2017
- Country
- BTSG United States
- AKRO United States
- Employees
- BTSG N/A
- AKRO N/A
- Industry
- BTSG
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- BTSG
- AKRO Health Care
- Exchange
- BTSG NYSE
- AKRO Nasdaq
- Market Cap
- BTSG 4.1B
- AKRO 3.9B
- IPO Year
- BTSG 2024
- AKRO 2019
- Fundamental
- Price
- BTSG $23.71
- AKRO $54.58
- Analyst Decision
- BTSG Strong Buy
- AKRO Strong Buy
- Analyst Count
- BTSG 9
- AKRO 6
- Target Price
- BTSG $23.50
- AKRO $82.50
- AVG Volume (30 Days)
- BTSG 3.2M
- AKRO 1.8M
- Earning Date
- BTSG 08-01-2025
- AKRO 08-08-2025
- Dividend Yield
- BTSG N/A
- AKRO N/A
- EPS Growth
- BTSG N/A
- AKRO N/A
- EPS
- BTSG 0.29
- AKRO N/A
- Revenue
- BTSG $11,858,835,000.00
- AKRO N/A
- Revenue This Year
- BTSG $11.55
- AKRO N/A
- Revenue Next Year
- BTSG $12.14
- AKRO N/A
- P/E Ratio
- BTSG $83.04
- AKRO N/A
- Revenue Growth
- BTSG 30.55
- AKRO N/A
- 52 Week Low
- BTSG $10.15
- AKRO $21.02
- 52 Week High
- BTSG $25.57
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- BTSG 60.33
- AKRO 68.00
- Support Level
- BTSG $22.48
- AKRO $53.05
- Resistance Level
- BTSG $23.27
- AKRO $56.49
- Average True Range (ATR)
- BTSG 1.01
- AKRO 2.44
- MACD
- BTSG 0.02
- AKRO -0.26
- Stochastic Oscillator
- BTSG 59.80
- AKRO 86.02
About BTSG BRIGHTSPRING HEALTH SERVICES INC
BrightSpring Health Services Inc is a home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. Its platform delivers clinical services and pharmacy solutions across Medicare, Medicaid, and commercially insured populations. Its segments include Pharmacy Solutions, Provider Services and others. It generates the majority of its revenue from the Pharmacy Solutions segment.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.